Establishment of Dementia Platform Korea and the Trial Ready Registry to advance Alzheimer's disease research in Korea

There is an abundance of high-quality clinical data and resources for Alzheimer's disease (AD) in Korea. To investigate therapeutic targets and biomarkers, and to progress the AD research field in Korea by standardizing the dementia dataset in Korea, the Trial Ready Registry (TRR) and Dementia Platform Korea (DPK) were developed. We designed the minimum common dataset (MCD) to collect data on patients with AD and human-derived materials, which consist of clinical data and positron emission tomography (PET) imaging, including both florbetaben (FBB)-PET and flutematamol (FMM)-PET. The TRR-DPK system is planning to enroll 3000 participants prospectively by 2028. As of December 2024, 1765 people have been recruited since 2020.We collected human-derived materials linked with imaging and clinical data to enable their distribution to qualified researchers for research purposes. We expect that the TRR-DPK system will improve AD research by providing researchers access to human-derived materials and quality-controlled data. HIGHLIGHTS: The Trial Ready Registry (TRR) was developed to standardize the dataset for Korean dementia research. At the end of the project, 3000 minimum common dataset (MCD) and blood specimens of participants would be stored and distributed. Currently, 1765 blood specimens and MCD data are available to for researchers in Korea. Blood specimens and MCD data, such as brain image data, and clinical data are available for Korean researchers at www.dpk.re.kr.